To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

How to transfigure the Wikipedia

Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.

Try it — you can delete it anytime.

Install in 5 seconds
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
Great Wikipedia has got greater.
.
Leo
Newton
Brights
Milds

Lonapegsomatropin

From Wikipedia, the free encyclopedia

Lonapegsomatropin
Clinical data
Trade namesSkytrofa
Other namesLonapegsomatropin-tcgd; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598
License data
Routes of
administration		Subcutaneous injection
Drug classGrowth hormone receptor agonist
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC1051H1627N269O317S9[C2H4O]4n

Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1][3] Lonapegsomatropin is a prodrug of somatropin.[1]

Lonapegsomatropin was approved for medical use in the United States in August 2021,[1][2][5] and in the European Union in January 2022.[3]

YouTube Encyclopedic

  • 1/2
    Views:
    2 164
    97 440
  • 3 Stocks That Are Analysts TOP Picks for 2021!!
  • Dividenden-Aristokraten ETF: Mit garantierten Dividenden durch die Krise?

Transcription

Medical uses

Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1][3]

History

The US Food and Drug Administration granted the application for lonapegsomatropin orphan drug designation.[6]

References

  1. ^ a b c d e "Skytrofa- lonapegsomatropin-tcgd injection, powder, lyophilized, for solution". DailyMed. Retrieved 30 September 2021.
  2. ^ a b "Skytrofa: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 August 2021.
  3. ^ a b c d "Skytrofa EPAR". European Medicines Agency. 10 November 2021. Retrieved 16 March 2022.
  4. ^ "Skytrofa Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  5. ^ "Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of Skytrofa (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency". Ascendis Pharma (Press release). 25 August 2021. Retrieved 25 August 2021.
  6. ^ Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. Public Domain This article incorporates text from this source, which is in the public domain.

Further reading

External links

  • Clinical trial number NCT02781727 for "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)" at ClinicalTrials.gov


Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

This page was last edited on 15 March 2024, at 00:13
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.
Contact WIKI 2
Introduction
Terms of Service
Privacy Policy